In today’s recent session, 14.7 million shares of the Sage Therapeutics Inc (NASDAQ:SAGE) have been traded, and its beta is 0.17. Most recently the company’s share price was $9.07, and it changed around $2.37 or 35.37% from the last close, which brings the market valuation of the company to $567.97M. SAGE at last check was trading at a discount to its 52-week high of $13.47, offering almost -48.51% off that amount. The share price’s 52-week low was $4.62, which indicates that the recent value has risen by an impressive 49.06% since then.
Sage Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.83. If we narrow it down even further, the data shows that 0 out of 19 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 15 recommended SAGE as a Hold, whereas 0 deemed it a Buy, and 1 rated it as Underweight. Sage Therapeutics Inc is expected to report earnings per share of -0.94 for the current quarter.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Instantly SAGE has been showing a green trend so far today with a performance of 35.37% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.15 on recent trading dayincreased the stock’s daily price by 0.87%. The company’s shares are currently up 67.03% year-to-date, but still up 33.19% over the last five days. On the other hand, Sage Therapeutics Inc (NASDAQ:SAGE) is 37.22% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to decrease their stock price by -81.4% from its current value. Analyst projections state that SAGE is forecast to be at a low of $5 and a high of $5.
Sage Therapeutics Inc (SAGE) estimates and forecasts
The year-over-year growth rate is expected to be 100.08%, up from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of 16.69M in revenue for the current quarter. 14 analysts expect Sage Therapeutics Inc to make 24.96M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 8.65M and 11.87M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 92.87%. Forecasts for the next quarter put sales growth at 110.22%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 13.20%. Sage Therapeutics Inc earnings are expected to increase by 46.80% in 2025, but the outlook is positive 36.05% per year for the next five years.
SAGE Dividends
Sage Therapeutics Inc’s next quarterly earnings report is expected to be released in July.
FMR LLC, with 9.6193% or 5.82 million shares worth $63.24 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
